Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Everest Medical

This article was originally published in The Gray Sheet

Executive Summary

Seeking financing "from numerous corporate and private sources" to continue operations, the firm notes in a Jan. 22 release announcing that losses for fourth quarter (ended Dec. 31) "were significantly higher than anticipated and have had a greater than expected negative impact on the company's cash position." Cash and short-term investments at the close of the year are estimated to total $726,196. The minimally invasive surgical instrument manufacturer expects to report a loss of $1.2 mil. for the quarter and $3.9 mil. for the year, compared to losses of $879,000 and $3.4 mil. for the comparable year ago periods, respectively. Sales are estimated to be $729,000 for the quarter, up 44%, and $2.3 mil. for the year, an advance of 84% from 1991. The firm notes that revenues got a boost from demand for its newly released bipolar forceps and scissors ("The Gray Sheet" March 16, 1992, I&W-7), but expenses were higher than anticipated due to "a significant write-down of obsolete inventory, manufacturing start-up expenses and reduced initial production yields of the new bipolar scissors, and production difficulties with a coagulating probe manufactured for another firm." Final sales and earnings results will be released in mid-February....

You may also be interested in...

COVID-19 Lockdown: India Pharma Manufacturing Limps Along Amid Challenges

Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.

Moderna Stands Alone With Single-Antigen Approach To COVID-19 Vaccine

Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.

Kansas City TCM Firm Persists With COVID-19 Claims Following US Regulators' Warning

Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts